CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3...
Phase 1
Barcelona, Spain and 33 other locations
primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% ...
Phase 2
Badalona, Spain and 11 other locations
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...
Phase 1, Phase 2
Barcelona, Spain and 12 other locations
to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate...
Phase 2
Barcelona, Spain and 7 other locations
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to ...
Phase 2, Phase 3
Barcelona, Spain and 29 other locations
Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...
Phase 1
Barcelona, Spain and 16 other locations
The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expa...
Phase 1, Phase 2
Barcelona, Spain and 7 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Barcelona, Spain and 131 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Barcelona, Cataluña, Spain and 44 other locations
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Phase 1
Barcelona, Cataluña, Spain and 20 other locations
Clinical trials
Research sites
Resources
Legal